{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:37:47Z","timestamp":1775320667481,"version":"3.50.1"},"reference-count":142,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cll.2018.10.007","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T01:44:52Z","timestamp":1545097492000},"page":"45-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection"],"prefix":"10.1016","volume":"39","author":[{"given":"Olga A.","family":"Timofeeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-62703-493-7_2","article-title":"Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury","volume":"1034","author":"Valenzuela","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1600-6143.2011.03926.x","article-title":"Banff 2011 meeting report: new concepts in antibody-mediated rejection","volume":"12","author":"Mengel","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trre.2016.10.004","article-title":"Acute antibody-mediated rejection in kidney transplant recipients","volume":"31","author":"Davis","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13092","article-title":"Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation","volume":"22","author":"Vaughn","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/HCO.0000000000000390","article-title":"Antibody-mediated rejection in the cardiac allograft: diagnosis, treatment and future considerations","volume":"32","author":"Hammond","year":"2017","journal-title":"Curr Opin Cardiol"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1600-6143.2011.03670.x","article-title":"Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema","volume":"11","author":"Drachenberg","year":"2011","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/ajt.12624","article-title":"Diagnosis of early pancreas graft failure via antibody-mediated rejection: single-center experience with 256 pancreas transplantations","volume":"14","author":"de Kort","year":"2014","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.cll.2018.10.007_bib9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1600-6143.2011.03729.x","article-title":"Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome","volume":"11","author":"Cantarovich","year":"2011","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.cll.2018.10.007_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.healun.2014.07.018","article-title":"De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation","volume":"33","author":"Morrell","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s40472-015-0074-5","article-title":"Antibody-mediated rejection in lung transplantation","volume":"2","author":"Kulkarni","year":"2015","journal-title":"Curr Transplant Rep"},{"issue":"6","key":"10.1016\/j.cll.2018.10.007_bib12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/TP.0000000000001391","article-title":"Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients","volume":"101","author":"Cheng","year":"2017","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5500\/wjt.v6.i3.564","article-title":"Updates on antibody-mediated rejection in intestinal transplantation","volume":"6","author":"Wu","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib15","series-title":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US)","year":"2016"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1223","article-title":"Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation","volume":"35","author":"Levine","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.5500\/wjt.v6.i4.719","article-title":"Acute antibody-mediated rejection after intestinal transplantation","volume":"6","author":"Wu","year":"2016","journal-title":"World J Transplant"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ki.2011.497","article-title":"Pros and cons for C4d as a biomarker","volume":"81","author":"Cohen","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","article-title":"Report from a consensus conference on antibody-mediated rejection in heart transplantation","volume":"30","author":"Kobashigawa","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.5858\/arpa.2013-0539-OA","article-title":"The presence of anti-HLA donor-specific antibodies in lung allograft recipients does not correlate with C4d immunofluorescence in transbronchial biopsy specimens","volume":"138","author":"Roberts","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2009.02813.x","article-title":"Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies","volume":"9","author":"Loupy","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.healun.2009.01.015","article-title":"Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes","volume":"28","author":"Wu","year":"2009","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.healun.2009.04.035","article-title":"Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection","volume":"28","author":"Kfoury","year":"2009","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1172\/JCI90597","article-title":"Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies","volume":"127","author":"Valenzuela","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.cll.2018.10.007_bib28","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/j.1600-6143.2007.01991.x","article-title":"C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation","volume":"7","author":"Smith","year":"2007","journal-title":"Am J Transplant"},{"issue":"13","key":"10.1016\/j.cll.2018.10.007_bib29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/ajt.13551","article-title":"Identifying subphenotypes of antibody-mediated rejection in kidney transplants","volume":"16","author":"Halloran","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.TP.0000441362.11232.48","article-title":"Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients","volume":"97","author":"Everly","year":"2014","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/ajt.13153","article-title":"Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation","volume":"15","author":"O'Leary","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/tri.12726","article-title":"Compartment-specific expression of natural killer cell markers in renal transplantation: immune profile in acute rejection","volume":"29","author":"Dos Santos","year":"2016","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOT.0b013e328355f1c2","article-title":"HLA class I antibody-mediated endothelial and smooth muscle cell activation","volume":"17","author":"Zhang","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOT.0b013e3283614a10","article-title":"Impact of donor-specific antibodies on results of liver transplantation","volume":"18","author":"O'Leary","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation","volume":"14","author":"O'Leary","year":"2014","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1600-6143.2007.02072.x","article-title":"Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation","volume":"8","author":"Lefaucheur","year":"2008","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.cll.2018.10.007_bib38","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1164\/rccm.201312-2160OC","article-title":"Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates","volume":"189","author":"Kim","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.cll.2018.10.007_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.healun.2014.06.015","article-title":"Early donor-specific antibodies in lung transplantation: risk factors and impact on survival","volume":"33","author":"Ius","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib41","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":"Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib42","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.humimm.2009.04.019","article-title":"Monitoring and treating posttransplant human leukocyte antigen antibodies","volume":"70","author":"Everly","year":"2009","journal-title":"Hum Immunol"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.healun.2010.05.006","article-title":"Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation","volume":"29","author":"Hachem","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.cll.2018.10.007_bib45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/TP.0b013e318244f7b8","article-title":"Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody","volume":"93","author":"Hodges","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.cll.2018.10.007_bib46","first-page":"93","article-title":"Pre-empting antibody-mediated rejection: a program of DSA monitoring and treatment can effectively prevent antibody mediated rejection","volume":"32","author":"Gilbert","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib47","first-page":"143","article-title":"Impact of donor specific HLA antibody monitoring after kidney transplantation","author":"Rao","year":"2014","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib48","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14893","article-title":"Human leukocyte antigens antibodies after lung transplantation: primary results of the HALT study","volume":"18","author":"Hachem","year":"2018","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.cll.2018.10.007_bib49","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/TP.0b013e3181a6bac5","article-title":"Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection","volume":"87","author":"Fehr","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria","volume":"77","author":"Redfield","year":"2016","journal-title":"Hum Immunol"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib51","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts","volume":"26","author":"Loupy","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ajt.12982","article-title":"Quantifying renal allograft loss following early antibody-mediated rejection","volume":"15","author":"Orandi","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.cll.2018.10.007_bib53","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ki.2010.556","article-title":"Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection","volume":"79","author":"Kimball","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.cll.2018.10.007_bib54","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.healun.2013.07.004","article-title":"Acute antibody-mediated rejection after lung transplantation","volume":"32","author":"Witt","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib55","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/ajt.14912","article-title":"Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation","volume":"18","author":"Ius","year":"2018","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib56","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/ajt.14752","article-title":"Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report","volume":"18","author":"Tambur","year":"2018","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/ajt.13076","article-title":"Survival in sensitized lung transplant recipients with perioperative desensitization","volume":"15","author":"Tinckam","year":"2015","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib58","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.humimm.2009.06.007","article-title":"Using real data for a virtual crossmatch","volume":"70","author":"Zachary","year":"2009","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib59","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/TP.0000000000000047","article-title":"The role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection","volume":"98","author":"Fine","year":"2014","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healun.2015.10.006","article-title":"The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children","volume":"35","author":"Ware","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib62","first-page":"1652931","article-title":"Renal transplant patients biopsied for cause and tested for C4d, DSA, and IgG subclasses and C1q: which humoral markers improve diagnosis and outcomes?","volume":"2017","author":"Cicciarelli","year":"2017","journal-title":"J\u00a0Immunol Res"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5500\/wjt.v6.i4.689","article-title":"Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: comparative analysis of exclusively anti-Cw vs anti-A and\/or -B antibodies","volume":"6","author":"Santos","year":"2016","journal-title":"World J Transplant"},{"issue":"10","key":"10.1016\/j.cll.2018.10.007_bib64","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.healun.2014.02.033","article-title":"Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation","volume":"33","author":"Smith","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib65","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ndt\/gfr429","article-title":"Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation","volume":"27","author":"Caro-Oleas","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ctr.12289","article-title":"Clinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodies","volume":"28","author":"Yoo","year":"2014","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib67","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2017.03.033","article-title":"Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis","volume":"92","author":"Gosset","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib68","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.cll.2018.10.007_bib69","first-page":"8316860","article-title":"The kinetics of anti-HLA antibodies in the first year after kidney transplantation: in whom and when should they be monitored?","volume":"2018","author":"de Castro","year":"2018","journal-title":"J\u00a0Transplant"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib70","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.healun.2016.05.020","article-title":"De-novo donor-specific anti-HLA antibodies 30\u00a0days after lung transplantation are associated with a worse outcome","volume":"35","author":"Le Pavec","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ndt\/gfw445","article-title":"Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen","volume":"32","author":"Zecher","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib72","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib73","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/ajt.13341","article-title":"The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib74","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MOT.0b013e3283626149","article-title":"Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation","volume":"18","author":"Wiebe","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib75","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib76","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib77","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/ajt.13259","article-title":"Development and impact of De Novo Anti-HLA antibodies in pediatric heart transplant recipients","volume":"15","author":"Chen","year":"2015","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-6143.2010.03383.x","article-title":"De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival","volume":"11","author":"Smith","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.healun.2015.08.008","article-title":"Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation","volume":"35","author":"Tran","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5144\/0256-4947.2018.97","article-title":"Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation","volume":"38","author":"Omrani","year":"2018","journal-title":"Ann Saudi Med"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib81","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1164\/rccm.201509-1857OC","article-title":"De Novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation","volume":"194","author":"Tikkanen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib82","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ccm.2017.07.008","article-title":"Acute rejection and antibody-mediated rejection in lung transplantation","volume":"38","author":"Hachem","year":"2017","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib83","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/ajt.13589","article-title":"Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics","volume":"16","author":"Roux","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fmed.2017.00155","article-title":"Characteristics of donor-specific antibodies associated with antibody-mediated rejection in lung transplantation","volume":"4","author":"Roux","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib85","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01248-2017","article-title":"Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation","volume":"50","author":"Verleden","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib86","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/ajt.13798","article-title":"HLA matching at the eplet level protects against chronic lung allograft dysfunction","volume":"16","author":"Walton","year":"2016","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib87","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/ajt.13734","article-title":"HLA-A, -B, -C, -DR, and -DQ matching in pancreas transplantation: effect on graft rejection and survival","volume":"16","author":"Rudolph","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2018.01.001","article-title":"Antibody mediated rejection due to de-novo DSA causing venous thrombosis of pancreas allograft - a case report","volume":"47","author":"Yadav","year":"2018","journal-title":"Transpl Immunol"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib89","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1111\/j.1600-6143.2012.04237.x","article-title":"Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver","volume":"12","author":"Abu-Elmagd","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib90","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOT.0b013e328339489c","article-title":"Immune monitoring in small bowel transplantation","volume":"15","author":"Sindhi","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.cll.2018.10.007_bib91","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1600-6143.2012.04332.x","article-title":"Immunologic challenges in small bowel transplantation","volume":"12","author":"Berger","year":"2012","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib92","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1111\/ajt.14685","article-title":"Antibody-mediated rejection in pediatric small bowel transplantation: capillaritis is a major determinant of C4d positivity in intestinal transplant biopsies","volume":"18","author":"Rabant","year":"2018","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib93","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.13700","article-title":"Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients","volume":"16","author":"Comoli","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib94","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.healun.2010.08.020","article-title":"Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients","volume":"30","author":"Chin","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib95","doi-asserted-by":"crossref","first-page":"518","DOI":"10.12659\/AOT.904867","article-title":"C1q test for identification of sensitized liver recipients at risk of early acute antibody-mediated rejection","volume":"22","author":"Kozlowski","year":"2017","journal-title":"Ann Transplant"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib96","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","article-title":"Combined posttransplant prophylactic IVIg\/anti-CD 20\/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study","volume":"89","author":"Loupy","year":"2010","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib97","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181880b35","article-title":"Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients","volume":"86","author":"Billing","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib98","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/tri.12934","article-title":"Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study","volume":"30","author":"Beland","year":"2017","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib99","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.kint.2017.04.041","article-title":"Deconstructing interstitial fibrosis and tubular atrophy: a step toward precision medicine in renal transplantation","volume":"92","author":"Mengel","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.cll.2018.10.007_bib100","first-page":"845040","article-title":"Clinical relevance of HLA antibody monitoring after kidney transplantation","volume":"2014","author":"Morath","year":"2014","journal-title":"J\u00a0Immunol Res"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"issue":"1S Suppl 1","key":"10.1016\/j.cll.2018.10.007_bib102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001818","article-title":"Of cells and microparticles: assets and liabilities of HLA antibody detection","volume":"102","author":"Liwski","year":"2018","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib103","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.12287","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA","volume":"13","author":"Reed","year":"2013","journal-title":"Am J Transplant"},{"issue":"1S Suppl 1","key":"10.1016\/j.cll.2018.10.007_bib104","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/TP.0000000000001817","article-title":"HLA diagnostics: evaluating DSA strength by titration","volume":"102","author":"Tambur","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cll.2018.10.007_bib105","first-page":"317","article-title":"Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival","author":"Everly","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib106","first-page":"333","article-title":"Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients","author":"Everly","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib107","first-page":"319","article-title":"Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients","author":"Everly","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib108","first-page":"389","article-title":"Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients","author":"Mohamed","year":"2011","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2012.01.028","article-title":"Immune monitoring of kidney allografts","volume":"60","author":"Ho","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2016030368","article-title":"Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss","volume":"28","author":"Viglietti","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib111","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/ajt.12462","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation","volume":"13","author":"Reed","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib112","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/TP.0000000000001420","article-title":"Conformational variants of the individual HLA-I antigens on luminex single antigen beads used in monitoring HLA antibodies: problems and solutions","volume":"101","author":"Jucaud","year":"2017","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib113","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.healun.2017.11.018","article-title":"The impact of screening method on HLA antibody detection before and after lung transplantation: a prospective pilot study","volume":"37","author":"Cao","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib114","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MOT.0b013e32836361f1","article-title":"Technical aspects of HLA antibody testing","volume":"18","author":"Gebel","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOT.0000000000000376","article-title":"Polyreactive natural antibodies in transplantation","volume":"22","author":"Zorn","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"issue":"7\u20138","key":"10.1016\/j.cll.2018.10.007_bib116","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.humimm.2017.05.007","article-title":"Understanding solid-phase HLA antibody assays and the value of MFI","volume":"78","author":"Sullivan","year":"2017","journal-title":"Hum Immunol"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib117","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MOT.0000000000000326","article-title":"Clinically relevant interpretation of solid phase assays for HLA antibody","volume":"21","author":"Bettinotti","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib118","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ctr.12529","article-title":"Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation","volume":"29","author":"Visentin","year":"2015","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.humimm.2015.09.012","article-title":"Evaluation of the iBeads assay as a tool for identifying class I HLA antibodies","volume":"76","author":"Visentin","year":"2015","journal-title":"Hum Immunol"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib120","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/eji.201445340","article-title":"Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation","volume":"45","author":"Visentin","year":"2015","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.cll.2018.10.007_bib121","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.healun.2014.02.013","article-title":"Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation","volume":"33","author":"Oaks","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.cll.2018.10.007_bib122","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.humimm.2013.06.035","article-title":"Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay","volume":"74","author":"Grenzi","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.cll.2018.10.007_bib123","first-page":"207","article-title":"2012 annual literature review of donor-specific HLA antibodies after organ transplantation","author":"Kaneku","year":"2012","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.cll.2018.10.007_bib124","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.humimm.2011.08.001","article-title":"Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report","volume":"72","author":"Poli","year":"2011","journal-title":"Hum Immunol"},{"issue":"6","key":"10.1016\/j.cll.2018.10.007_bib125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.humimm.2011.02.012","article-title":"Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?","volume":"72","author":"Pereira","year":"2011","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.cll.2018.10.007_bib126","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.yexmp.2016.01.008","article-title":"Are complement-fixing antibodies against denatured HLA antigens clinically relevant?","volume":"100","author":"Visentin","year":"2016","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0000000000000840","article-title":"Evidence to support a contribution of polyreactive antibodies to HLA serum reactivity","volume":"100","author":"Gao","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yexmp.2015.11.023","article-title":"Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection","volume":"100","author":"Cai","year":"2016","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"10.1016\/j.cll.2018.10.007_bib129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/tan.13185","article-title":"Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: a systematic review and meta-analysis","volume":"91","author":"Courtwright","year":"2018","journal-title":"HLA"},{"issue":"1","key":"10.1016\/j.cll.2018.10.007_bib130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/TP.0000000000000285","article-title":"Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection","volume":"99","author":"Touzot","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cll.2018.10.007_bib131","first-page":"9874261","article-title":"Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature","volume":"2016","author":"Tran","year":"2016","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib132","article-title":"Prognostic tools to assess candidacy for and efficacy of antibody removal therapy","author":"Pinelli","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cll.2018.10.007_bib133","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1745-6215-15-107","article-title":"Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial","volume":"15","author":"Eskandary","year":"2014","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib134","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/01.TP.0000441824.95510.97","article-title":"Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept","volume":"97","author":"Krisl","year":"2014","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.cll.2018.10.007_bib135","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1111\/petr.12347","article-title":"HLA desensitization with bortezomib in a highly sensitized pediatric patient","volume":"18","author":"May","year":"2014","journal-title":"Pediatr Transplant"},{"issue":"6","key":"10.1016\/j.cll.2018.10.007_bib136","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/TP.0000000000000132","article-title":"Differential effect of bortezomib on HLA class I and class II antibody","volume":"98","author":"Philogene","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib137","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3346\/jkms.2014.29.5.648","article-title":"Use of bortezomib as anti-humoral therapy in kidney transplantation","volume":"29","author":"Yang","year":"2014","journal-title":"J\u00a0Korean Med Sci"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib138","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/petr.12300","article-title":"Bortezomib use in a pediatric cardiac transplant center","volume":"18","author":"Zinn","year":"2014","journal-title":"Pediatr Transplant"},{"issue":"5","key":"10.1016\/j.cll.2018.10.007_bib139","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TXD.0000000000000526","article-title":"A\u00a0phased desensitization protocol with rituximab and bortezomib for highly sensitized kidney transplant candidates","volume":"1","author":"Ide","year":"2015","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.cll.2018.10.007_bib140","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3349\/ymj.2015.56.6.1638","article-title":"The effect of bortezomib on antibody-mediated rejection after kidney transplantation","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med J"},{"issue":"9","key":"10.1016\/j.cll.2018.10.007_bib141","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: comparison of MFI, C1q, and titer information","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cll.2018.10.007_bib142","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.kint.2018.03.015","article-title":"Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection","volume":"94","author":"Viglietti","year":"2018","journal-title":"Kidney Int"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271218312034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271218312034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:34:04Z","timestamp":1775316844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271218312034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0272271218312034"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2018.10.007","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2018.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}